MoonLake Immunotherapeutics 8-K

What Happened

• MoonLake Immunotherapeutics (MLTX) announced on May 22, 2026 that it entered a Master Commercial Supply Agreement (Vetter MCSA) and a related Capacity Agreement with Vetter Pharma International GmbH (through Vetter Pharma‑Fertigung GmbH & Co. KG). The parties previously had a master development agreement (effective October 27, 2021) under which Vetter provided development and manufacturing services for MoonLake’s product candidate sonelokimab. The MCSA is a master agreement that will be supplemented by product‑specific schedules defining services and pricing.

Key Details

• Date signed: May 22, 2026; prior relationship established under a master development agreement effective October 27, 2021.
• Capacity commitment: MoonLake must provide an aggregate demand forecast; annual demands in the initial term are binding (the “MoonLake Commitment”), with a specified Maximum Quantity and Minimum Quantity. Vetter will reserve filling capacity equivalent to the Maximum Quantity per year.
• Financial obligations: MoonLake may owe capacity compensation or a portion of lost net revenue if it fails to meet Minimum Quantity or ordered amounts; Vetter may adjust product prices for documented cost increases (e.g., wages, energy, materials).
• Termination and protections: Either party can terminate for uncured material breach (60‑day cure), or without cause with 12 months’ notice; immediate termination for bankruptcy. Vetter may terminate on certain change‑of‑control scenarios; MoonLake can terminate if Vetter is acquired by a competitor active in dermatology/inflammatory diseases before end of 2029. The agreements include standard provisions on defects, delivery, regulatory matters, IP and confidentiality.

Why It Matters

• This agreement secures a commercial manufacturing and dedicated filling capacity partner for MoonLake, reducing manufacturing uncertainty for sonelokimab or other products that may be produced under product schedules.
• It also creates binding capacity and potential payment obligations: if demand falls short of committed minimums, MoonLake may face capacity compensation or lost‑revenue payments, which could affect future cash flow and cost structure.
• Price‑adjustment and termination provisions define how costs and strategic changes (e.g., change of control) could impact manufacturing continuity. Full contract texts will be filed as exhibits to MoonLake’s Form 10‑Q for the quarter ending June 30, 2026 for investors to review.